ID   HDAC3_HUMAN             Reviewed;         428 AA.
AC   O15379; D3DQE1; O43268; Q9UEI5; Q9UEV0;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   15-MAR-2017, entry version 187.
DE   RecName: Full=Histone deacetylase 3;
DE            Short=HD3;
DE            EC=3.5.1.98;
DE   AltName: Full=RPD3-2;
DE   AltName: Full=SMAP45;
GN   Name=HDAC3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RC   TISSUE=Spleen, and T-cell;
RX   PubMed=9464271; DOI=10.1006/bbrc.1997.8033;
RA   Dangond F., Hafler D.A., Tong J.K., Randall J., Kojima R., Utku N.,
RA   Gullans S.R.;
RT   "Differential display cloning of a novel human histone deacetylase
RT   (HDAC3) cDNA from PHA-activated immune cells.";
RL   Biochem. Biophys. Res. Commun. 242:648-652(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Fibroblast;
RX   PubMed=9346952; DOI=10.1074/jbc.272.44.28001;
RA   Yang W.-M., Yao Y.-L., Sun J.-M., Davie J.R., Seto E.;
RT   "Isolation and characterization of cDNAs corresponding to an
RT   additional member of the human histone deacetylase gene family.";
RL   J. Biol. Chem. 272:28001-28007(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9501169; DOI=10.1073/pnas.95.6.2795;
RA   Emiliani S., Fischle W., van Lint C., Al-Abed Y., Verdin E.;
RT   "Characterization of a human RPD3 ortholog, HDAC3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:2795-2800(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=10051405; DOI=10.1006/geno.1998.5645;
RA   Mahlknecht U., Emiliani S., Najfeld V., Young S., Verdin E.;
RT   "Genomic organization and chromosomal localization of the human
RT   histone deacetylase 3 gene.";
RL   Genomics 56:197-202(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 95-353 AND 407-428.
RA   Lynch E.D., Lee M.K., King M.-C.;
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   INTERACTION WITH NRIP1.
RX   PubMed=11006275; DOI=10.1074/jbc.M004821200;
RA   Wei L.-N., Hu X., Chandra D., Seto E., Farooqui M.;
RT   "Receptor-interacting protein 140 directly recruits histone
RT   deacetylases for gene silencing.";
RL   J. Biol. Chem. 275:40782-40787(2000).
RN   [9]
RP   INTERACTION WITH DAXX.
RX   PubMed=10669754; DOI=10.1128/MCB.20.5.1784-1796.2000;
RA   Li H., Leo C., Zhu J., Wu X., O'Neil J., Park E.-J., Chen J.D.;
RT   "Sequestration and inhibition of Daxx-mediated transcriptional
RT   repression by PML.";
RL   Mol. Cell. Biol. 20:1784-1796(2000).
RN   [10]
RP   INTERACTION WITH HDAC9.
RX   PubMed=10655483; DOI=10.1073/pnas.97.3.1056;
RA   Zhou X., Richon V.M., Rifkind R.A., Marks P.A.;
RT   "Identification of a transcriptional repressor related to the
RT   noncatalytic domain of histone deacetylases 4 and 5.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:1056-1061(2000).
RN   [11]
RP   IDENTIFICATION IN A COMPLEX WITH NCOR1 AND NCOR2.
RX   PubMed=10860984; DOI=10.1073/pnas.97.13.7202;
RA   Wen Y.-D., Perissi V., Staszewski L.M., Yang W.-M., Krones A.,
RA   Glass C.K., Rosenfeld M.G., Seto E.;
RT   "The histone deacetylase-3 complex contains nuclear receptor
RT   corepressors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:7202-7207(2000).
RN   [12]
RP   INTERACTION WITH HDAC7.
RX   PubMed=11466315; DOI=10.1074/jbc.M104935200;
RA   Fischle W., Dequiedt F., Fillion M., Hendzel M.J., Voelter W.,
RA   Verdin E.;
RT   "Human HDAC7 histone deacetylase activity is associated with HDAC3 in
RT   vivo.";
RL   J. Biol. Chem. 276:35826-35835(2001).
RN   [13]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=11533236; DOI=10.1128/MCB.21.19.6470-6483.2001;
RA   Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N.,
RA   Downing J.R., Meyers S., Hiebert S.W.;
RT   "ETO, a target of t(8;21) in acute leukemia, makes distinct contacts
RT   with multiple histone deacetylases and binds mSin3A through its
RT   oligomerization domain.";
RL   Mol. Cell. Biol. 21:6470-6483(2001).
RN   [14]
RP   INTERACTION WITH HDAC10.
RX   PubMed=11861901; DOI=10.1093/nar/30.5.1114;
RA   Tong J.J., Liu J., Bertos N.R., Yang X.-J.;
RT   "Identification of HDAC10, a novel class II human histone deacetylase
RT   containing a leucine-rich domain.";
RL   Nucleic Acids Res. 30:1114-1123(2002).
RN   [15]
RP   SUMOYLATION.
RX   PubMed=12032081; DOI=10.1093/emboj/21.11.2682;
RA   Kirsh O., Seeler J.-S., Pichler A., Gast A., Mueller S., Miska E.,
RA   Mathieu M., Harel-Bellan A., Kouzarides T., Melchior F., Dejean A.;
RT   "The SUMO E3 ligase RanBP2 promotes modification of the HDAC4
RT   deacetylase.";
RL   EMBO J. 21:2682-2691(2002).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND COMPONENT OF THE N-COR
RP   COMPLEX WITH NCOR2 AND TBL1X.
RX   PubMed=10809664;
RA   Guenther M.G., Lane W.S., Fischle W., Verdin E., Lazar M.A.,
RA   Shiekhattar R.;
RT   "A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-
RT   repeat protein linked to deafness.";
RL   Genes Dev. 14:1048-1057(2000).
RN   [17]
RP   COMPONENT OF THE N-COR COMPLEX WITH NCOR2 AND HDAC3.
RX   PubMed=10944117; DOI=10.1093/emboj/19.16.4342;
RA   Li J., Wang J., Wang J., Nawaz Z., Liu J.M., Qin J., Wong J.;
RT   "Both corepressor proteins SMRT and N-CoR exist in large protein
RT   complexes containing HDAC3.";
RL   EMBO J. 19:4342-4350(2000).
RN   [18]
RP   INTERACTION WITH BCOR.
RX   PubMed=10898795;
RA   Huynh K.D., Fischle W., Verdin E., Bardwell V.J.;
RT   "BCoR, a novel corepressor involved in BCL-6 repression.";
RL   Genes Dev. 14:1810-1823(2000).
RN   [19]
RP   COMPONENT OF THE N-COR COMPLEX WITH NCOR1; NCOR2; GPS2; TBL1R AND
RP   TBL1X.
RX   PubMed=11931768; DOI=10.1016/S1097-2765(02)00468-9;
RA   Zhang J., Kalkum M., Chait B.T., Roeder R.G.;
RT   "The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK
RT   pathway through the integral subunit GPS2.";
RL   Mol. Cell 9:611-623(2002).
RN   [20]
RP   COMPONENT OF THE N-COR COMPLEX WITH TBL1R; TBL1X AND CORO2A.
RX   PubMed=12628926; DOI=10.1093/emboj/cdg120;
RA   Yoon H.-G., Chan D.W., Huang Z.-Q., Li J., Fondell J.D., Qin J.,
RA   Wong J.;
RT   "Purification and functional characterization of the human N-CoR
RT   complex: the roles of HDAC3, TBL1 and TBLR1.";
RL   EMBO J. 22:1336-1346(2003).
RN   [21]
RP   INTERACTION WITH APEX1.
RX   PubMed=14633989; DOI=10.1093/emboj/cdg595;
RA   Bhakat K.K., Izumi T., Yang S.H., Hazra T.K., Mitra S.;
RT   "Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation
RT   of the parathyroid hormone gene.";
RL   EMBO J. 22:6299-6309(2003).
RN   [22]
RP   INTERACTION WITH DACH1.
RX   PubMed=14525983; DOI=10.1074/jbc.M310021200;
RA   Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K.,
RA   Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.;
RT   "DACH1 inhibits transforming growth factor-beta signaling through
RT   binding Smad4.";
RL   J. Biol. Chem. 278:51673-51684(2003).
RN   [23]
RP   INTERACTION WITH SRY.
RX   PubMed=15297880; DOI=10.1038/sj.emboj.7600352;
RA   Thevenet L., Mejean C., Moniot B., Bonneaud N., Galeotti N.,
RA   Aldrian-Herrada G., Poulat F., Berta P., Benkirane M.,
RA   Boizet-Bonhoure B.;
RT   "Regulation of human SRY subcellular distribution by its
RT   acetylation/deacetylation.";
RL   EMBO J. 23:3336-3345(2004).
RN   [24]
RP   INTERACTION WITH JMJD2A.
RX   PubMed=15927959; DOI=10.1074/jbc.M413687200;
RA   Gray S.G., Iglesias A.H., Lizcano F., Villanueva R., Camelo S.,
RA   Jingu H., Teh B.T., Koibuchi N., Chin W.W., Kokkotou E., Dangond F.;
RT   "Functional characterization of JMJD2A, a histone deacetylase- and
RT   retinoblastoma-binding protein.";
RL   J. Biol. Chem. 280:28507-28518(2005).
RN   [25]
RP   INTERACTION WITH INSM1.
RX   PubMed=16569215; DOI=10.1042/BJ20051669;
RA   Liu W.D., Wang H.W., Muguira M., Breslin M.B., Lan M.S.;
RT   "INSM1 functions as a transcriptional repressor of the neuroD/beta2
RT   gene through the recruitment of cyclin D1 and histone deacetylases.";
RL   Biochem. J. 397:169-177(2006).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [27]
RP   INTERACTION WITH INSM1.
RX   PubMed=18417529; DOI=10.1677/JOE-08-0001;
RA   Wang H.W., Muguira M., Liu W.D., Zhang T., Chen C., Aucoin R.,
RA   Breslin M.B., Lan M.S.;
RT   "Identification of an INSM1-binding site in the insulin promoter:
RT   negative regulation of the insulin gene transcription.";
RL   J. Endocrinol. 198:29-39(2008).
RN   [28]
RP   INTERACTION WITH NKAP.
RX   PubMed=19409814; DOI=10.1016/j.immuni.2009.02.011;
RA   Pajerowski A.G., Nguyen C., Aghajanian H., Shapiro M.J., Shapiro V.S.;
RT   "NKAP is a transcriptional repressor of notch signaling and is
RT   required for T cell development.";
RL   Immunity 30:696-707(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-424, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   INTERACTION WITH CCAR2 AND MEF2D, AND SUBCELLULAR LOCATION.
RX   PubMed=21030595; DOI=10.1074/jbc.M110.153270;
RA   Chini C.C., Escande C., Nin V., Chini E.N.;
RT   "HDAC3 is negatively regulated by the nuclear protein DBC1.";
RL   J. Biol. Chem. 285:40830-40837(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   INTERACTION WITH BEND3.
RX   PubMed=21914818; DOI=10.1242/jcs.086603;
RA   Sathyan K.M., Shen Z., Tripathi V., Prasanth K.V., Prasanth S.G.;
RT   "A BEN-domain-containing protein associates with heterochromatin and
RT   represses transcription.";
RL   J. Cell Sci. 124:3149-3163(2011).
RN   [33]
RP   FUNCTION IN DEACETYLATION OF MAPK14.
RX   PubMed=21444723; DOI=10.1128/MCB.01205-10;
RA   Pillai V.B., Sundaresan N.R., Samant S.A., Wolfgeher D., Trivedi C.M.,
RA   Gupta M.P.;
RT   "Acetylation of a conserved lysine residue in the ATP binding pocket
RT   of p38 augments its kinase activity during hypertrophy of
RT   cardiomyocytes.";
RL   Mol. Cell. Biol. 31:2349-2363(2011).
RN   [34]
RP   FUNCTION IN DEACETYLATION OF H3K27, AND IDENTIFICATION IN A COMPLEX
RP   WITH BCL6 AND NCOR2.
RX   PubMed=23911289; DOI=10.1016/j.celrep.2013.06.016;
RA   Hatzi K., Jiang Y., Huang C., Garrett-Bakelman F., Gearhart M.D.,
RA   Giannopoulou E.G., Zumbo P., Kirouac K., Bhaskara S., Polo J.M.,
RA   Kormaksson M., Mackerell A.D. Jr., Xue F., Mason C.E., Hiebert S.W.,
RA   Prive G.G., Cerchietti L., Bardwell V.J., Elemento O., Melnick A.;
RT   "A hybrid mechanism of action for BCL6 in B cells defined by formation
RT   of functionally distinct complexes at enhancers and promoters.";
RL   Cell Rep. 4:578-588(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-424, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   FUNCTION, INTERACTION WITH XBP1, SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=25190803; DOI=10.1074/jbc.M114.571984;
RA   Martin D., Li Y., Yang J., Wang G., Margariti A., Jiang Z., Yu H.,
RA   Zampetaki A., Hu Y., Xu Q., Zeng L.;
RT   "Unspliced X-box-binding protein 1 (XBP1) protects endothelial cells
RT   from oxidative stress through interaction with histone deacetylase
RT   3.";
RL   J. Biol. Chem. 289:30625-30634(2014).
CC   -!- FUNCTION: Responsible for the deacetylation of lysine residues on
CC       the N-terminal part of the core histones (H2A, H2B, H3 and H4),
CC       and some other non-histone substrates. Histone deacetylation gives
CC       a tag for epigenetic repression and plays an important role in
CC       transcriptional regulation, cell cycle progression and
CC       developmental events. Histone deacetylases act via the formation
CC       of large multiprotein complexes. Participates in the BCL6
CC       transcriptional repressor activity by deacetylating the H3 'Lys-
CC       27' (H3K27) on enhancer elements, antagonizing EP300
CC       acetyltransferase activity and repressing proximal gene
CC       expression. Probably participates in the regulation of
CC       transcription through its binding to the zinc-finger transcription
CC       factor YY1; increases YY1 repression activity. Required to repress
CC       transcription of the POU1F1 transcription factor. Acts as a
CC       molecular chaperone for shuttling phosphorylated NR2C1 to PML
CC       bodies for sumoylation (PubMed:21444723, PubMed:23911289).
CC       Contributes, together with XBP1 isoform 1, to the activation of
CC       NFE2L2-mediated HMOX1 transcription factor gene expression in a
CC       PI(3)K/mTORC2/Akt-dependent signaling pathway leading to
CC       endothelial cell (EC) survival under disturbed flow/oxidative
CC       stress (PubMed:25190803). {ECO:0000269|PubMed:21444723,
CC       ECO:0000269|PubMed:23911289, ECO:0000269|PubMed:25190803}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of an N(6)-acetyl-lysine residue of
CC       a histone to yield a deacetylated histone.
CC   -!- SUBUNIT: Interacts with HDAC7 and HDAC9. Forms a heterologous
CC       complex at least with YY1. Interacts with DAXX, HDAC10 and DACH1.
CC       Found in a complex with NCOR1 and NCOR2. Component of the N-Cor
CC       repressor complex, at least composed of NCOR1, NCOR2, HDAC3,
CC       TBL1X, TBL1R, CORO2A and GPS2. Interacts with BCOR, MJD2A/JHDM3A,
CC       NRIP1, PRDM6 and SRY. Interacts with BTBD14B. Interacts with
CC       GLIS2. Interacts (via the DNA-binding domain) with NR2C1; the
CC       interaction recruits phosphorylated NR2C1 to PML bodies for
CC       sumoylation. Component of the Notch corepressor complex. Interacts
CC       with CBFA2T3 and NKAP. Interacts with APEX1; the interaction is
CC       not dependent on the acetylated status of APEX1. Interacts with
CC       and deacetylates MAPK14. Interacts with ZMYND15. Interacts with
CC       SMRT/NCOR2 and BCL6 on DNA enhancer elements. Interacts with INSM1
CC       (PubMed:10655483, PubMed:10669754, PubMed:10860984,
CC       PubMed:10898795, PubMed:11006275, PubMed:11466315,
CC       PubMed:11533236, PubMed:11861901, PubMed:14525983,
CC       PubMed:14633989, PubMed:15297880, PubMed:15927959,
CC       PubMed:16569215, PubMed:18417529, PubMed:19409814,
CC       PubMed:23911289). Interacts with XBP1 isoform 1; the interaction
CC       occurs in endothelial cell (EC) under disturbed flow
CC       (PubMed:25190803). Interacts (via C-terminus) with CCAR2 (via N-
CC       terminus). Interacts with and deacetylates MEF2D. Interacts with
CC       BEND3. Interacts with NKAPL (By similarity).
CC       {ECO:0000250|UniProtKB:O88895, ECO:0000269|PubMed:10655483,
CC       ECO:0000269|PubMed:10669754, ECO:0000269|PubMed:10860984,
CC       ECO:0000269|PubMed:10898795, ECO:0000269|PubMed:11006275,
CC       ECO:0000269|PubMed:11466315, ECO:0000269|PubMed:11533236,
CC       ECO:0000269|PubMed:11861901, ECO:0000269|PubMed:14525983,
CC       ECO:0000269|PubMed:14633989, ECO:0000269|PubMed:15297880,
CC       ECO:0000269|PubMed:15927959, ECO:0000269|PubMed:16569215,
CC       ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19409814,
CC       ECO:0000269|PubMed:21030595, ECO:0000269|PubMed:21914818,
CC       ECO:0000269|PubMed:23911289, ECO:0000269|PubMed:25190803}.
CC   -!- INTERACTION:
CC       O43823:AKAP8; NbExp=10; IntAct=EBI-607682, EBI-1237481;
CC       Q9ULX6:AKAP8L; NbExp=5; IntAct=EBI-607682, EBI-357530;
CC       Q9UKG1:APPL1; NbExp=2; IntAct=EBI-607682, EBI-741243;
CC       Q7L2E3:DHX30; NbExp=3; IntAct=EBI-607682, EBI-1211456;
CC       P08393:ICP0 (xeno); NbExp=3; IntAct=EBI-607682, EBI-6148881;
CC       O60341:KDM1A; NbExp=4; IntAct=EBI-607682, EBI-710124;
CC       Q969R5:L3MBTL2; NbExp=6; IntAct=EBI-607682, EBI-739909;
CC       P43356:MAGEA2B; NbExp=4; IntAct=EBI-607682, EBI-5650739;
CC       Q9UIS9:MBD1; NbExp=3; IntAct=EBI-607682, EBI-867196;
CC       P01106:MYC; NbExp=6; IntAct=EBI-607682, EBI-447544;
CC       O75376:NCOR1; NbExp=5; IntAct=EBI-607682, EBI-347233;
CC       Q9Y5X4:NR2E3; NbExp=2; IntAct=EBI-607682, EBI-7216962;
CC       P48552:NRIP1; NbExp=2; IntAct=EBI-607682, EBI-746484;
CC       Q8CBD1:Nrip1 (xeno); NbExp=2; IntAct=EBI-607682, EBI-1771626;
CC       P60510:PPP4C; NbExp=4; IntAct=EBI-607682, EBI-1046072;
CC       Q15022:SUZ12; NbExp=7; IntAct=EBI-607682, EBI-1264675;
CC       P12504:vif (xeno); NbExp=2; IntAct=EBI-607682, EBI-779991;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21030595}.
CC       Cytoplasm {ECO:0000269|PubMed:25190803}. Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:21030595}. Note=Colocalizes with XBP1 and AKT1
CC       in the cytoplasm (PubMed:25190803). Predominantly expressed in the
CC       nucleus in the presence of CCAR2. {ECO:0000269|PubMed:21030595,
CC       ECO:0000269|PubMed:25190803}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=RPD3-2B;
CC         IsoId=O15379-1; Sequence=Displayed;
CC       Name=2; Synonyms=RPD3-2A;
CC         IsoId=O15379-2; Sequence=VSP_002079;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- INDUCTION: Up-regulated by disturbed flow in umbilical vein
CC       endothelial cells in vitro (PubMed:25190803).
CC   -!- PTM: Sumoylated in vitro. {ECO:0000269|PubMed:12032081}.
CC   -!- SIMILARITY: Belongs to the histone deacetylase family. HD type 1
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HDAC3ID40804ch5q31.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U66914; AAC52038.1; -; mRNA.
DR   EMBL; U75697; AAB88241.1; -; mRNA.
DR   EMBL; U75696; AAB88240.1; -; mRNA.
DR   EMBL; AF005482; AAB87752.1; -; mRNA.
DR   EMBL; AF039703; AAC98927.1; -; mRNA.
DR   EMBL; AF059650; AAC26509.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61915.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61916.1; -; Genomic_DNA.
DR   EMBL; BC000614; AAH00614.1; -; mRNA.
DR   EMBL; AF053138; AAC08351.1; -; Genomic_DNA.
DR   EMBL; AF053137; AAC08351.1; JOINED; Genomic_DNA.
DR   EMBL; AF053139; AAC08352.1; -; Genomic_DNA.
DR   CCDS; CCDS4264.1; -. [O15379-1]
DR   PIR; JC5834; JC5834.
DR   RefSeq; NP_003874.2; NM_003883.3. [O15379-1]
DR   UniGene; Hs.519632; -.
DR   PDB; 4A69; X-ray; 2.06 A; A/B=1-376.
DR   PDBsum; 4A69; -.
DR   ProteinModelPortal; O15379; -.
DR   SMR; O15379; -.
DR   BioGrid; 114368; 215.
DR   DIP; DIP-24253N; -.
DR   IntAct; O15379; 76.
DR   MINT; MINT-196172; -.
DR   STRING; 9606.ENSP00000302967; -.
DR   BindingDB; O15379; -.
DR   ChEMBL; CHEMBL1829; -.
DR   DrugBank; DB05015; Belinostat.
DR   DrugBank; DB05651; MGCD-0103.
DR   DrugBank; DB06603; Panobinostat.
DR   DrugBank; DB05223; SB939.
DR   DrugBank; DB02546; Vorinostat.
DR   GuidetoPHARMACOLOGY; 2617; -.
DR   iPTMnet; O15379; -.
DR   PhosphoSitePlus; O15379; -.
DR   BioMuta; HDAC3; -.
DR   EPD; O15379; -.
DR   MaxQB; O15379; -.
DR   PaxDb; O15379; -.
DR   PeptideAtlas; O15379; -.
DR   PRIDE; O15379; -.
DR   DNASU; 8841; -.
DR   Ensembl; ENST00000305264; ENSP00000302967; ENSG00000171720. [O15379-1]
DR   GeneID; 8841; -.
DR   KEGG; hsa:8841; -.
DR   UCSC; uc003llf.3; human. [O15379-1]
DR   CTD; 8841; -.
DR   DisGeNET; 8841; -.
DR   GeneCards; HDAC3; -.
DR   HGNC; HGNC:4854; HDAC3.
DR   HPA; CAB005583; -.
DR   HPA; HPA052052; -.
DR   MIM; 605166; gene.
DR   neXtProt; NX_O15379; -.
DR   OpenTargets; ENSG00000171720; -.
DR   PharmGKB; PA29228; -.
DR   eggNOG; KOG1342; Eukaryota.
DR   eggNOG; COG0123; LUCA.
DR   GeneTree; ENSGT00530000062889; -.
DR   HOGENOM; HOG000225180; -.
DR   HOVERGEN; HBG057112; -.
DR   InParanoid; O15379; -.
DR   KO; K11404; -.
DR   OMA; QLNHKIC; -.
DR   OrthoDB; EOG091G067J; -.
DR   PhylomeDB; O15379; -.
DR   TreeFam; TF352182; -.
DR   Reactome; R-HSA-1368071; NR1D1 (REV-ERBA) represses gene expression.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-193670; p75NTR negatively regulates cell cycle via SC1.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3214815; HDACs deacetylate histones.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   SABIO-RK; O15379; -.
DR   SignaLink; O15379; -.
DR   SIGNOR; O15379; -.
DR   ChiTaRS; HDAC3; human.
DR   GeneWiki; HDAC3; -.
DR   GenomeRNAi; 8841; -.
DR   PMAP-CutDB; O15379; -.
DR   PRO; PR:O15379; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000171720; -.
DR   CleanEx; HS_HDAC3; -.
DR   ExpressionAtlas; O15379; baseline and differential.
DR   Genevisible; O15379; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000118; C:histone deacetylase complex; TAS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0030332; F:cyclin binding; IPI:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0004407; F:histone deacetylase activity; IMP:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0032041; F:NAD-dependent histone deacetylase activity (H3-K14 specific); IEA:UniProtKB-EC.
DR   GO; GO:0051059; F:NF-kappaB binding; IPI:UniProtKB.
DR   GO; GO:0033558; F:protein deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IDA:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; TAS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; IMP:UniProtKB.
DR   GO; GO:0042993; P:positive regulation of transcription factor import into nucleus; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; IDA:UniProtKB.
DR   GO; GO:0051225; P:spindle assembly; IMP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.800.20; -; 1.
DR   InterPro; IPR000286; His_deacetylse.
DR   InterPro; IPR003084; His_deacetylse_1.
DR   InterPro; IPR023801; His_deacetylse_dom.
DR   PANTHER; PTHR10625; PTHR10625; 1.
DR   Pfam; PF00850; Hist_deacetyl; 1.
DR   PIRSF; PIRSF037913; His_deacetylse_1; 1.
DR   PRINTS; PR01270; HDASUPER.
DR   PRINTS; PR01271; HISDACETLASE.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromatin regulator;
KW   Complete proteome; Cytoplasm; Hydrolase; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN         1    428       Histone deacetylase 3.
FT                                /FTId=PRO_0000114696.
FT   REGION        3    316       Histone deacetylase.
FT   ACT_SITE    135    135       {ECO:0000250}.
FT   MOD_RES     424    424       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1     15       MAKTVAYFYDPDVGN -> MIVFKPYQASQHDMCR (in
FT                                isoform 2). {ECO:0000303|PubMed:9346952}.
FT                                /FTId=VSP_002079.
FT   VARIANT     411    411       N -> S (in dbSNP:rs34901743).
FT                                /FTId=VAR_033988.
FT   CONFLICT    359    359       R -> L (in Ref. 1; AAC52038).
FT                                {ECO:0000305}.
FT   STRAND        5      8       {ECO:0000244|PDB:4A69}.
FT   TURN         11     14       {ECO:0000244|PDB:4A69}.
FT   HELIX        27     38       {ECO:0000244|PDB:4A69}.
FT   HELIX        41     44       {ECO:0000244|PDB:4A69}.
FT   STRAND       45     48       {ECO:0000244|PDB:4A69}.
FT   HELIX        55     58       {ECO:0000244|PDB:4A69}.
FT   TURN         59     61       {ECO:0000244|PDB:4A69}.
FT   HELIX        64     72       {ECO:0000244|PDB:4A69}.
FT   TURN         75     77       {ECO:0000244|PDB:4A69}.
FT   HELIX        78     81       {ECO:0000244|PDB:4A69}.
FT   HELIX        82     88       {ECO:0000244|PDB:4A69}.
FT   STRAND       91     94       {ECO:0000244|PDB:4A69}.
FT   HELIX       100    119       {ECO:0000244|PDB:4A69}.
FT   STRAND      124    128       {ECO:0000244|PDB:4A69}.
FT   STRAND      145    147       {ECO:0000244|PDB:4A69}.
FT   HELIX       149    157       {ECO:0000244|PDB:4A69}.
FT   TURN        158    160       {ECO:0000244|PDB:4A69}.
FT   STRAND      164    168       {ECO:0000244|PDB:4A69}.
FT   STRAND      170    172       {ECO:0000244|PDB:4A69}.
FT   HELIX       175    180       {ECO:0000244|PDB:4A69}.
FT   TURN        181    183       {ECO:0000244|PDB:4A69}.
FT   STRAND      185    194       {ECO:0000244|PDB:4A69}.
FT   HELIX       212    214       {ECO:0000244|PDB:4A69}.
FT   STRAND      217    223       {ECO:0000244|PDB:4A69}.
FT   HELIX       229    247       {ECO:0000244|PDB:4A69}.
FT   STRAND      250    255       {ECO:0000244|PDB:4A69}.
FT   HELIX       258    260       {ECO:0000244|PDB:4A69}.
FT   HELIX       273    284       {ECO:0000244|PDB:4A69}.
FT   STRAND      290    293       {ECO:0000244|PDB:4A69}.
FT   HELIX       300    314       {ECO:0000244|PDB:4A69}.
FT   HELIX       329    332       {ECO:0000244|PDB:4A69}.
FT   TURN        333    335       {ECO:0000244|PDB:4A69}.
FT   STRAND      337    339       {ECO:0000244|PDB:4A69}.
FT   HELIX       352    367       {ECO:0000244|PDB:4A69}.
SQ   SEQUENCE   428 AA;  48848 MW;  94485C1EBDCF5AD0 CRC64;
     MAKTVAYFYD PDVGNFHYGA GHPMKPHRLA LTHSLVLHYG LYKKMIVFKP YQASQHDMCR
     FHSEDYIDFL QRVSPTNMQG FTKSLNAFNV GDDCPVFPGL FEFCSRYTGA SLQGATQLNN
     KICDIAINWA GGLHHAKKFE ASGFCYVNDI VIGILELLKY HPRVLYIDID IHHGDGVQEA
     FYLTDRVMTV SFHKYGNYFF PGTGDMYEVG AESGRYYCLN VPLRDGIDDQ SYKHLFQPVI
     NQVVDFYQPT CIVLQCGADS LGCDRLGCFN LSIRGHGECV EYVKSFNIPL LVLGGGGYTV
     RNVARCWTYE TSLLVEEAIS EELPYSEYFE YFAPDFTLHP DVSTRIENQN SRQYLDQIRQ
     TIFENLKMLN HAPSVQIHDV PADLLTYDRT DEADAEERGP EENYSRPEAP NEFYDGDHDN
     DKESDVEI
//
